» Articles » PMID: 36766487

Hormonal and Metabolic Factors Influence the Action of Progesterone on the Endometrium of Women with Polycystic Ovary Syndrome

Overview
Specialty Radiology
Date 2023 Feb 11
PMID 36766487
Authors
Affiliations
Soon will be listed here.
Abstract

Hormonal and metabolic factors may influence endometrial quality and interfere with the action of progesterone. Therefore, the aim of our study was to address this issue. Participants were recruited from an outpatient reproductive endocrinology clinic at an academic tertiary medical care centre. All subjects underwent endometrial biopsy (EB) in the follicular phase of the cycle prior to treatment. Thereafter, they were treated with micronized progesterone (400 mg/day × 10 days intravaginally) from days 14-28 of the next cycle. A second EB was performed between days 21-24 of the cycle (the second phase). The metabolic and hormonal serum levels were evaluated during the implantation window. EB samples were analysed using light microscopy for histomorphometric analysis. The endometrium of women with Polycystic Ovarian Syndrome (PCOS) in the second phase demonstrated a uniform surface epithelium with less leukocyte infiltration and an absence of apoptotic figures compared to the control group. ( < 0.021). The thickness of the surface epithelium in the second phase of the PCOS group correlated positively with free and bioavailable testosterone values. The number of stromal cells increases with increasing insulin levels. Our results suggest that histomorphometric abnormalities of the endometrium persist and are linked to androgen and insulin levels despite progesterone supplementation in PCOS.

Citing Articles

Polycystic ovary syndrome: emerging stem cell therapies.

Busari K, Tulay P Rev Assoc Med Bras (1992). 2024; 70(6):e20231436.

PMID: 39045951 PMC: 11288272. DOI: 10.1590/1806-9282.20231436.


The association of CYP11A1 gene polymorphisms with the polycystic ovary syndrome patients.

Alyousif S, Ozbakir B, Ozay A, Tulay P Rev Assoc Med Bras (1992). 2024; 70(7):e20231293.

PMID: 39045925 PMC: 11262315. DOI: 10.1590/1806-9282.20231293.


Effect of polycystic ovary syndrome on the life quality of young women.

Tandogan O, Yakit Ak E, Akdemir A, Oskay U, Callioglu N Rev Assoc Med Bras (1992). 2024; 70(4):e20231368.

PMID: 38716947 PMC: 11068381. DOI: 10.1590/1806-9282.20231368.


Is polycystic ovary syndrome a risk factor for depression and anxiety?: a cross-sectional study.

Gunkaya O, Tekin A, Bestel A, Arslan O, Sahin F, Taymur B Rev Assoc Med Bras (1992). 2024; 70(3):e20230918.

PMID: 38655994 PMC: 11042827. DOI: 10.1590/1806-9282.20230918.


Influence of Phenotypes on the Metabolic Syndrome of Women with Polycystic Ovary Syndrome over a Six-Year Follow-Up in Brazil.

Soares-Jr J, Hayashida S, Marcondes J, Maciel G, Barcellos C, Maffazioli G Biomedicines. 2023; 11(12).

PMID: 38137483 PMC: 10741024. DOI: 10.3390/biomedicines11123262.


References
1.
Sharpe A, Morley L, Tang T, Norman R, Balen A . Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019; 12:CD013505. PMC: 6915832. DOI: 10.1002/14651858.CD013505. View

2.
Simoes R, Soares Jr J, Simoes M, Nader H, Baracat M, Maciel G . Small leucine-rich proteoglycans (SLRPs) in the endometrium of polycystic ovary syndrome women: a pilot study. J Ovarian Res. 2017; 10(1):54. PMC: 5549392. DOI: 10.1186/s13048-017-0349-9. View

3.
de Medeiros S, Yamamoto M, de Medeiros M, Barbosa B, Soares J, Baracat E . Changes in clinical and biochemical characteristics of polycystic ovary syndrome with advancing age. Endocr Connect. 2020; 9(2):74-89. PMC: 6993261. DOI: 10.1530/EC-19-0496. View

4.
Giordano L, Giordano M, Celia Teixeira Gomes R, Simoes R, Baracat M, Giordano M . Effects of clinical and metabolic variables and hormones on the expression of immune protein biomarkers in the endometrium of women with polycystic ovary syndrome and normal-cycling controls. Gynecol Endocrinol. 2022; 38(6):508-515. DOI: 10.1080/09513590.2022.2061454. View

5.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W . Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91(11):4237-45. DOI: 10.1210/jc.2006-0178. View